secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0000950170-23-021495
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics Q1 net loss $9.9M; cash $51.8M; REASSURE trial on track
---------------------------------------------------------------------------

- Net loss Q1 2023 $9.9M vs $3.5M Q1 2022; non-GAAP net loss $7.4M vs $5.6M.
- Cash and investments $51.8M as of March 31, 2023; expected to fund operations until mid-2024.
- R&D expense $6.4M (up from $3.4M) due to REASSURE; G&A $2.1M (down from $3.9M).
- REASSURE trial enrollment ongoing; completion expected H1 2024; interim analysis H2 2023.
- Approximately 12.9M ordinary shares outstanding as of April 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/0000950170-23-021495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017023021495/itrm-20230512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer